- Home
- SLS vs AVR Comparison
SLS vs AVR Comparison
Compare SLS & AVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLS
- AVR
- Stock Information
- Founded
- SLS 2012
- AVR 1999
- Country
- SLS United States
- AVR Australia
- Employees
- SLS N/A
- AVR N/A
- Industry
- SLS Biotechnology: Pharmaceutical Preparations
- AVR
- Sector
- SLS Health Care
- AVR
- Exchange
- SLS Nasdaq
- AVR NYSE
- Market Cap
- SLS 165.6M
- AVR 162.1M
- IPO Year
- SLS N/A
- AVR 2024
- Fundamental
- Price
- SLS $1.66
- AVR $3.07
- Analyst Decision
- SLS Strong Buy
- AVR Strong Buy
- Analyst Count
- SLS 1
- AVR 4
- Target Price
- SLS $7.00
- AVR $16.50
- AVG Volume (30 Days)
- SLS 2.8M
- AVR 199.6K
- Earning Date
- SLS 08-12-2025
- AVR 08-16-2025
- Dividend Yield
- SLS N/A
- AVR N/A
- EPS Growth
- SLS N/A
- AVR N/A
- EPS
- SLS N/A
- AVR N/A
- Revenue
- SLS N/A
- AVR $2,493,000.00
- Revenue This Year
- SLS N/A
- AVR $33.26
- Revenue Next Year
- SLS N/A
- AVR $194.42
- P/E Ratio
- SLS N/A
- AVR N/A
- Revenue Growth
- SLS N/A
- AVR N/A
- 52 Week Low
- SLS $0.77
- AVR $2.34
- 52 Week High
- SLS $2.27
- AVR $8.79
- Technical
- Relative Strength Index (RSI)
- SLS 41.18
- AVR N/A
- Support Level
- SLS $1.75
- AVR N/A
- Resistance Level
- SLS $1.96
- AVR N/A
- Average True Range (ATR)
- SLS 0.12
- AVR 0.00
- MACD
- SLS -0.04
- AVR 0.00
- Stochastic Oscillator
- SLS 18.56
- AVR 0.00
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
About AVR ANTERIS TECHNOLOGIES GLOBAL CORP
Anteris Technologies Global Corp. is a structural heart company committed to discovering, developing and commercializing medical devices designed to improve the quality of life for patients with aortic stenosis. Its product, the DurAVR THV system, represents a product opportunity in a new THV class of single-piece heart valves, for the treatment of aortic stenosis. Its DurAVR THV system consists of a single-piece, biomimetic valve made with its proprietary ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold.